Curis adds Pienta to its board
Curis names Johns Hopkins urology and oncology professor Pienta to its board
LEXINGTON, Mass. (AP) -- Drug developer Curis Inc. said Monday that it named Dr. Kenneth Pienta to its board.
Pienta currently serves as a professor of urology, oncology and pharmacology and molecular sciences at Johns Hopkins University's school of medicine. He also has served as head of Curis' clinical and scientific advisory board and has advised the company on other matters, Curis said.
Curis CEO Dan Passeri said Pienta's significant experience in cancer patient care will add further scientific depth to the board.
Curis shares rose 2 cents to $3.51 in midday trading.
